10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The problem was the company's worsening bottom line.

Why 10x Genomics' Soaring Q4 Revenue Wasn't Enough to Impress Investors

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2020 Results - Earnings Call Transcript

Q4 2020 revenue growth of 49% over prior year

10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: 10x Genomics (TXG) Q4 Earnings Expected to Decline

PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after market close on Wednesday, February 17, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

10x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference

10X Genomics is a cutting edge, single-cell assay hardware, software and consumables company. Don't feel bad, I don't understand all of that either.

10X Genomics: Richly Priced, But Likely Worth It

Moderna

Pfizer

Teladoc

Veeva Systems

Here's how these big businesses became enormous during a year most of us would rather forget.

These 5 Large-Cap Healthcare Stocks Had the Best Gains in 2020

10X Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Earnings Call Transcript

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Quick Version Earnings Call Transcript

PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.

10x Genomics Reports Third Quarter 2020 Financial Results

PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

10x Genomics to Participate in the Stifel 2020 Healthcare Conference

PLEASANTON, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

10x Genomics to Report Third Quarter Financial Results on November 10, 2020

Corvus Pharmaceuticals

Incyte

Zai Lab Ltd.

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Week In Review: $1.5 Billion Total In Week's China Deals

Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB

10x Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions

10x Genomics, Inc. has performed outstandingly well since the COVID-19 induced lows of March, more than doubling in this time.

10x Genomics: Overvaluation Leads To A Short-Term Hold/Trim Ranking

PLEASANTON, Calif., Sept.  15, 2020  (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A common stock, which included the exercise in full of the underwriters’ option to purchase 600,000 additional shares of its Class A common stock, at a public offering price of $110.00 per share. Including the option exercise, the aggregate gross proceeds from the offering were $506 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares were offered by the Company.

10x Genomics Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Allscripts Healthcare Solutions

NextGen Healthcare Inc

3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes

PLEASANTON, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions. 10x Genomics is offering 4,000,000 shares of its Class A common stock, plus up to an additional 600,000 shares of its Class A common stock that the underwriters have the right to purchase at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by the Company. The offering is expected to close on September 15, 2020, subject to customary closing conditions.

10x Genomics Announces Pricing of Upsized Public Offering

PLEASANTON, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company pursuant to a registration statement filed with the Securities and Exchange Commission. All of the shares are being offered by the Company. Additionally, the Company intends to grant the underwriters a 30-day option to purchase up to 525,000 additional shares of the Company’s Class A common stock.

10x Genomics Announces Launch of a Follow-On Public Offering

Innoviva

Jazz Pharmaceuticals

Theravance Biopharma

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC

PLEASANTON, Calif., Sept.  01, 2020  (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

10x Genomics to Participate in the Morgan Stanley 2020 Healthcare Conference

10x Genomics went public in September 2019.

10x Genomics Enjoys Investor Support As Stock Rebounds

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2020 Results - Earnings Call Transcript

PLEASANTON, Calif., Aug.  11, 2020  (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2020.

News for 10X Genomics Stock (TXG)